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   We investigated the effects of cysteinyl-leukotriene type 1 receptor antagonist, 
montelukast (MK), and compared them with those of methylprednisolone (MP) in an 
allergic asthma model. Rats sensitized to ovalbumin (OVA) received repeated 
intratracheal exposure to OVA for up to three consecutive days. Pretreatment with MK 
or MP before OVA exposure inhibited late airway response (LAR) and reduced cellular 
infiltration into the bronchial submucosa after the triple OVA. The amount of 
N-acetyl-leukotriene E4 in the bile was significantly reduced by pretreatment with MK 
or MP, suggesting that both drugs reduced the production of cysteinyl-leukotrienes 
(cysLTs) in the lungs. In the in vitro study, when the fragments of lungs that had been 
repeatedly pretreated with MK or MP and exposed to OVA were removed and incubated 
with OVA, the co-addition of either drug significantly reduced cysLT production. In 
contrast, the cysLT production following the addition of OVA to the lung fragments that 
had not received in vivo pretreatment with either drug was inhibited by MK, but not by 
MP. These results indicate that MK and MP inhibit LAR by suppressing the infiltration 
of inflammatory cells into the bronchial submucosa and thereby inhibiting the 
production of cysLTs in the lungs, and that MK, but not MP, may inhibit cysLT 
production directly. The different effects on cysLT production between the two drugs 
may provide a rationale for the use of combination therapy with cysLT1RAs and steroids 








   Asthma, one of the most prevalent disorders among industrialized nations, is 
characterized by reversible bronchoconstriction, increased mucous secretion, and 
complex airway inflammation (Busse and Rosenwasser, 2003). Inhalation of a specific 
antigen in allergic subjects usually results in dual responses, an immediate airway 
response (IAR) and a late airway response (LAR) (Nagy et al., 1982). The mechanisms 
for LAR are considered to be causally related to infiltration of eosinophils and other 
inflammatory cells into the bronchial submucosa following the IAR (Bousquet et al., 
1990). Recent basic and clinical studies indicate that cysteinyl-leukotrienes (cysLTs) 
play an important role in both the responses of bronchial asthma (Smith, 1996) via the 
following effects on the airway system: induction of profound bronchoconstriction 
(Dahlen et al., 1980), enhancement of vascular leakage (Dahlen et al., 1981), 
enhancement of mucous secretion in the bronchi (Coles et al., 1983), and induction of 
chemotactic activity of eosinophils (Laitinen et al., 1993; Henderson et al., 1996). The 
cellular origins of cysLTs in the lungs are considered to be mast cells, eosinophils, 
basophils, monocytes-macrophages, and cell-cell interactions, such as those between 
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neutrophils and platelets (Samuelsson et al., 1987; Maclouf and Murphy, 1988). Several 
new drugs known as “leukotriene modifiers” have been developed to modulate the 
actions of cysLTs (Busse, 1998; Drazen et al., 1999). Namely, cysLT type1 receptor 
antagonists (cysLT1RAs) and 5-lipoxygenase inhibitors block the effects of cysLTs on 
airway tissue and decrease the generation of cysLTs, respectively. On the basis of 
clinical studies, cysLT1RAs have been shown to be as effective at reducing asthma 
symptoms (Reiss et al., 1997) and inflammatory cell infiltration into the bronchial 
submucosa as 5-lipoxygenase inhibitors (Nakamura et al., 1998). The cysLT1RA has 
been shown to inhibit airway eosinophilia, hyper-responsiveness and microvascular 
leakage in mice after allergen challenge (Blain and Sirois, 2000). It has been reported 
that montelukast (MK), a cysLT1RA, additively or synergistically improves lung 
function and patients’ symptoms when administered in conjunction with β-adrenergic 
receptor agonists or steroids (Reiss et al., 1997; Price et al., 2003).  
   Although cysLT1RAs are effective in both acute and chronic bronchial asthma and 
are recommended for clinical use as maintenance therapy (Busse and Lemanske, 2001; 
Naureckas and Solway, 2001; Price et al., 2003), the precise mechanisms by which 
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these drugs achieve their effects remain unclear (Leff, 2001). Consequently, we 
investigated the effects of MK in an allergic asthma model after repeated antigen 
exposure by estimating pulmonary resistance (RL), pathological findings, and biliary 
excretion of N-acetyl-LTE4 (A-LTE4) as indices of the production of cysLTs in the lungs 
(Powell et al., 1995; Kodani et al., 2000). In addition, to examine the direct effects of 
MK or methylprednisolone (MP) on cysLT production in allergic lungs, we performed 
in vitro experiments using chopped lung fragments. On the other hand, steroids still 
remain the first-line drug for the treatment of acute exacerbation of asthma (National 
Institutes of Health/World Health Organization, 2002). Although there have been 
numerous studies concerning the mechanisms of steroids on allergic reactions, the 
effects of steroids on the generation of leukotrienes remain controversial (Barnes, 1998; 
Colamorea et al., 1999; Vachier et al., 2001; Barnes and Adcock, 2003). We therefore 
compared the mechanisms of the effects of MK on cysLT production in the lungs with 




MATERIALS AND METHODS 
Materials 
All experimental protocols were approved by the institutional animal care and use 
committee of the School of Medicine, Fukuoka University. The cysLT1RA (montelukast 
sodium; MK) was donated by Merck & Co., Inc. (Rahway, NJ). Methylprednisolone 
sodium succinate (MP) and Bordetella pertussis vaccine were purchased from Pfizer 
Manufacturing (Puurs, Belgium) and Wako Chemicals (Osaka, Japan), respectively. 
 
Sensitization of rats     
Male Brown-Norway rats (Seakku-Yoshitomi, Fukuoka, Japan) that were 6 to 8 weeks 
old and weighed around 250 g were used for the study. Active sensitization against OVA 
was performed by subcutaneous injection of sterile normal saline (1 ml) containing 1 
mg OVA (grade II; Sigma, St. Louis, MO) and 200 mg aluminum hydroxide (Sigma).  
Bordetella pertussis vaccine (50 µl) containing 6x109 heat-killed bacilli was given 
intraperitoneally as an adjuvant. Three days later, sterile normal saline (1 ml) containing 
1 mg OVA and 200 mg aluminum hydroxide was subcutaneously injected for a booster 
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effect. All animals selected for these studies were used from 14 to 28 days after the first 
injection. 
 
Evaluation of the effects of MK and MP 
Sensitized rats were divided into groups by the number of OVA exposures and the 
different schedules of drug administration, as shown in Fig.1. With respect to the 
number of OVA exposures, the sensitized rats were daily challenged by inhalation of 
OVA aerosol for two successive days (Days 1 and 2) in the triple OVA exposure 
experiment. For this purpose, the inhalation of 0.25% OVA aerosol was accomplished 
by placing the rats for 20 min on each occasion in a 10-liter Plexiglass chamber 
connected to an ultrasonic nebulizer known as the “Comfort-mini” (Model-10; Sin-Ei 
Industries, Inc., Ageo, Japan). The next day (Day 3), the final OVA challenge was 
performed by intratracheal (i.t.) administration of 0.1 ml of a 1.7% OVA solution, as 
shown in Fig.1A and B. Ovalbumin grade V (Sigma) was used for OVA exposure (Abe 
et al., 2001). In the double OVA exposure, the sensitized rats were challenged by 
inhalation of OVA aerosol only for one day, and the final OVA challenge was performed 
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by i.t. on the next day (OVA Day 2). In the single OVA exposure, the rats were 
challenged by i.t. administration without any previous inhalation of OVA aerosol 
(Fig.1C). The control indicates the OVA sensitized rats received triple administration of 
saline. Administration of MK or MP was performed according to two different regimens 
on OVA Day 3; in one schedule the drug was administered before every OVA exposure 
(triple pretreatment), whereas in the other the drug was administered only before the 3rd 
OVA exposure (single pretreatment), as shown in Fig.1A and B, respectively. MK was 
dissolved in sterile saline, and the rats received the drugs gastrically at a rate of 10 
mg/kg 1 hour before the start of the i.t. OVA challenge. MP was dissolved in the 
dissolving solution supplied by the manufacturer (Pfizer Manufacturing) and injected 
into the rats intramuscularly at a rate of 10 mg/kg 1 hour before the start of the i.t. 
challenge.  
 
Measurement of pulmonary resistance (RL) 
The rats were anesthetized by intraperitoneal (i.p.) injection with urethane (1 g/kg, 25 % 
wt/vol). The tip of the tracheal tube (a 5 cm length of polyethylene tubing (PE-240)) 
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was inserted into the trachea through an open tracheostomy. The transpulmonary 
pressure was determined by monitoring the difference between the pressure in the 
external end of the tracheal cannula and the esophageal cannula using a Statham 
differential transducer (DP-45; Validyne Engineering Corp., Northridge, CA). The 
intrapleural pressure was measured through a water-filled cannula (PE-240) that was 
placed in the lower third of the esophagus and connected to one port of a differential 
pressure transducer (DP-45; Validyne).  A Fleisch pneumotachograph and a differential 
transducer were used to monitor the respiratory flow rate (PULMOS-II system; M.I.P.S., 
Osaka, Japan). RL was estimated under artificial ventilation with a Harvard Apparatus 
Rodent Respirator (Millis, Bedford, MA) at a respiration rate of 70 breaths/min and a 
tidal volume of 3.5 ml (Abe et al., 2001). The RL was measured before the challenge 
(baseline value). After challenge with OVA, the RL was measured at 1, 5, 10, 15, 30, 45, 
and 60 min, and thereafter RL was examined every 30 min for 6 hours. 
    
Histological and cytological examination  
At 6 hours after the i.t. administration of OVA, the rats were exsanguinated by cutting 
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the abdominal aorta. The trachea was joined to a tube with a three-way stopcock 
connected to a reservoir containing the fixative. The lungs were fixed in situ by the i.t. 
administration of 8% formaldehyde solution given at a pressure of 15 cmH2O. The 
lungs were then stained with Hematoxylin-Eosin (HE) to assess the degree of 
inflammation. 
   Bronchoalveolar lavage (BAL) was performed via the tracheal cannula using 2x10 
ml of saline containing 1 mM EDTA. The BALF was centrifuged at 300 x g for 5 min at 
4°C and the cell pellet resuspended in 1.0 ml sterile saline with 0.2% rat serum. The 
total cell count was determined by adding 50 µl of the cell suspension to 50 µl Trypan 
blue stain and counting cells under a light microscope. The differential cell count was 
carried out from the smear preparation stained with Diff-Quik (International Reagents 
Corp., Kobe, Japan) and counting 200 cells at random under x200 magnification. The 
cells were identified by standard morphology. 
 
Measurement of A-LTE4 in bile  
The rats were anesthetized with urethane and then the common bile duct was exposed 
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and cannulated by a PE-20 polyethylene tube (15 cm in length) after the ligation of the 
duodenal end.  The rats were allowed to stabilize for a period of 2 hours prior to i.t. 
challenge with OVA.  The bile was collected every hour on ice in 1.5 ml Eppendorf 
tubes under a stream of argon before and after the i.t. challenge, and then was stored at 
–80°C until analyzed. A-LTE4 was measured in bile using precolumn 
extraction/reversed-phase high performance liquid chromatography (RP-HPLC) 
according to the previously reported method (Powell et al., 1995; Kodani et al., 2000).  
Briefly, ethanol was added to the aliquots (including [3H]-LTE4 as an internal standard) 
to give a final concentration of 15%.  After adjusting to pH 3.0-3.5, the samples were 
loaded onto a Sep-PAK cartridge (Waters Corporation, Milford, MA). Methanol-eluted 
fractions passed through the minicolumn were concentrated under reduced pressure by a 
Speed Vac Concentrator (Savant Instruments Inc., Hicksville, NY). After resuspension 
with 150 µl of HPLC solvent A, 75 µl of the concentrated fraction was injected onto a 
Novapak C18, 5 µm column (0.39 x 15 cm) (Waters Corporation).  The A-LTE4 and 
LTE4 fractions were collected using a fraction collector (Model 201; Gilson S.A.S, 
Villiers le Bel, France), then evaporated under reduced pressure. The residue was 
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analyzed by enzyme immunoassay (EIA) using a Leukotriene C4/D4/E4 EIA kit 
(Amersham, Buckinghamshire, UK) according to the manufacturer's instructions. The 
values of LTC4, LTD4, and LTE4 were normalized based on the recovery rates of 
[3H]-LTE4 (31.6±1.0%, n=27). 
 
In vitro experiments for estimation of cysLT production in lung fragments 
The lungs were removed from the actively sensitized rats with or without previous OVA 
exposure, and then the large bronchi or blood vessels were dissected from the lung 
tissue. The tissues were chopped into small pieces (approximately 2x2x2 mm) by fine 
scissors. The chopped lung tissue (300 mg) was preincubated in Tyrodes’ buffer with or 
without co-addition of MK or MP for 5 min at 37°C, and further incubated for 30 min at 
37°C after the addition of OVA solution (100 µg/ml). For incubation in the controls, 
saline was added instead of OVA. After terminating the reaction by addition of cold 
ethanol, LTs were partially purified through a Sep-Pak cartridge (Waters Corporation). 
After evaporation of methanol eluates under reduced pressure and resuspension with 
HPLC solvent A, LTC4, LTD4, and LTE4 were separated with the Novapak C18 column 
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and each fraction was collected. LTC4 and LTD4 fractions were assayed using a 
CysLT-EIA kit (Cayman Chemicals, Ann Arbor, MI), and the LTE4 fraction was assayed 
using a LTE4-EIA kit (Cayman Chemicals). The sum of the amounts of LTC4, LTD4, and 
LTE4 was considered the cysLT amount.  
 
High-performance liquid chromatography (HPLC) 
The HPLC system consisted of a Model 600 controller, a 717 autosampler (Waters 
Corporation) and the Novapak C18 column. We used solvent A 
(acetonitrile/methanol/water/acetic acid, 30:12:58:0.03, vol/vol) containing 0.03% 
ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA-free acid; Dojindo, Kumamoto, 
Japan), and solvent B consisting of acetonitrile/methanol/water/acetic acid 
(68:12:20:0.01, vol/vol) containing 0.001% EDTA. All solvents were adjusted to pH 5.6 
with ammonia solution (Nacalai, Kyoto, Japan). The mobile phase began with solvent A 
and then was changed to solvent B at 20 min. The flow rate was 1 ml/min. The retention 
times for LTC4, A-LTE4, LTD4, and LTE4 were approximately 4.2, 9.1, 13.1, and 15.1 





Data are reported as the means+SEM. The statistical analysis was performed using the 
General Linear Models Procedure in SAS (Statistical Analysis System). A p value of 










Time course for changes of RL 
 
Figure 2 shows the time course for changes of RL after the third OVA challenge. 
Although control rats given 0.1 ml saline i.t. did not show any significant changes in RL 
up to 6 hours after the challenge, rats that received the triple OVA exposure showed 
prominent LAR. As shown in Fig. 2A, triple pretreatment with MK or MP significantly 
suppressed LAR, but the intervention with MP seemed to be more potent than that with 
MK. The control indicates the OVA sensitized rats received triple i.t. administration of 
saline. Single pretreatment with MK or MP only before the 3rd OVA exposure also 
significantly inhibited LAR, but the inhibition by either drug was less than that by the 
triple pretreatment (Fig. 2B).  
   Table 1 shows the peak height of IAR and LAR after the 3rd OVA exposure with or 
without pretreatment with MK or MP. Although triple pretreatment with MP 
significantly suppressed IAR, both single and triple pretreatment with MK tended to 
suppress IAR, but not significantly. On the other hand, both drugs with either 
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administration schedule significantly suppressed LAR.  
 
Cytological studies in BALF 
Cytological studies were performed to examine the changes of total leukocyte number 
and the recovery of cellular differentiation in BALF, and to evaluate the effects of MK 
and MP on the infiltration of inflammatory cells into airway space. The results are 
shown in Fig. 3. Alveolar macrophages made up more than 90% of recovered cells in 
BALF after the saline i.t. challenge (control). The triple OVA exposure resulted in 
significantly more leukocytes in BALF than in the controls, and showed a diathesis 
toward increase in leukocyte number compared with the double exposure (OVA Day 2). 
Concerning cellular differentiation, eosinophils and neutrophils were the predominant 
cells, and the lymphocyte number also increased significantly. As shown in Fig. 3A and 
3B, repeated pretreatment before every OVA exposure with either drug suppressed the 
accumulation of all types of leukocytes in BALF, but the effect of the single 
pretreatment only before the 3rd exposure was weaker than that of the triple 
pretreatment. The single pretreatment with MK or MP did not significantly inhibit 
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infiltration of eosinophils in the airway space after the 3rd exposure. 
 
Histological studies  
When the rats received double or triple OVA exposures, histological findings in 
bronchial tissue were examined at 6 hours after the last exposure. As shown in Fig. 4A 
and B, an extremely high infiltration of inflammatory cells including eosinophils and 
neutrophils was recognized in the bronchial submucosa after the 3rd exposure, in 
comparison with the double exposure. While triple pretreatment with MK suppressed 
the infiltration of inflammatory cells into the bronchial submucosa, as shown in Fig. 4C, 
that with MP almost completely inhibited the cellular infiltration (Fig. 4D). On the other 
hand, when the other administration schedule, single pretreatment only before the 3rd 
OVA exposure, was used to evaluate the effects of both drugs, pretreatment with either 
MK or MP also moderately suppressed the infiltration of inflammatory cells into the 
bronchial submucosa, and these suppressions were less potent than those by triple 




N-acetyl-LTE4 level in bile  
In order to examine the time course of the generation of cysLTs in the lungs, we 
measured A-LTE4 excretion in biliary fluid after the 3rd exposure to OVA. Saline 
administration did not change the level of A-LTE4 (control). The 3rd OVA challenge 
resulted in significantly greater biliary excretion of A-LTE4 up to 6 hours after challenge. 
As shown in Fig. 5A, triple pretreatment with MK or MP significantly reduced A-LTE4 
excretion in biliary fluid, but pretreatment with MP seemed to be more potent than that 
with MK. On the other hand, the single pretreatment with either drug only before the 
3rd challenge also significantly reduced A-LTE4 excretion in bile (Fig. 5B), suggesting 
that these two drugs suppressed cysLT production in the lungs after antigen challenge.  
 
Relationship between N-acetyl-LTE4 level and leukocyte number in BALF 
When the A-LTE4 level in bile and leukocyte number in BALF from the individual rats 
were plotted, a significant correlation was observed between the two parameters, as 
shown in Fig. 6A and B. The correlation coefficient for this relationship (OVA Day 3 + 
saline) was 0.849 (p=0.0051). When rats were pretreated with MK or MP, the 
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relationship between the A-LTE4 level in bile and the leukocyte number in BALF was 
well correlated under the single pretreatment regimen (Fig. 6B), but not under the triple 
pretreatment regimen (Fig. 6A). The correlation coefficients in the former treatment 
were 0.719 (p=0.0266) for the single pretreatment with MK and 0.862 (p=0.0092) for 
that with MP, respectively. 
 
In vitro production of cysLTs from chopped lung fragments 
In order to examine the influence of MK or MP on the production of cysLTs in lung 
tissue after stimulation with the antigen, the chopped sensitized lung fragments without 
previous OVA exposure were incubated with OVA in Tyrodes’ buffer in the presence or 
absence of either drug at various concentrations for 30 min at 37°C. An approximately 
three-fold higher amount of cysLT was produced in the chopped lung fragments 
supplemented with OVA compared to those supplemented with saline (control), as 
shown in Fig. 7. When MK was added at various concentrations (1–100 µg/ml), the 
production of cysLTs was significantly suppressed at the highest concentration (100 
µg/ml). In contrast, the addition of MP at 1–100 µg/ml seemed to increase the 
JPET #74922 
 21
production of cysLTs, but not to a significant extent in comparison with that by OVA 
alone. The cysLT amount in the presence of MK (100 µg/ml) was significantly lower 
than that in the presence of MP (100 µg/ml). Next, the influence of MK or MP on cysLT 
production was evaluated in the lungs that were removed after repeated exposures to the 
antigen (Fig. 8). The lungs were removed from rats that were sequentially exposed to 
OVA for the last 2 days without pretreatment of MK or MP (Fig. 8A). The lungs were 
chopped into small pieces and then incubated with OVA in the buffer with or without 
co-addition of either MK (100 µg/ml) or MP (100 µg/ml) for 30 min at 37°C. While the 
amount of cysLT from the chopped lung fragments was significantly greater by the 
addition of OVA than by the addition of saline (control), co-addition of MK, but not MP, 
significantly inhibited cysLT production. The cysLT amount in the presence of MK was 
significantly lower than that in the presence of MP (Fig. 8A). In another trial, rats were 
daily challenged by inhalation of OVA aerosol for two successive days with or without 
repeated pretreatment of MK (10 mg/kg) or MP (10 mg/kg) before every challenge. On 
the next day, the lungs were removed and chopped into small pieces. When the chopped 
lung fragments were incubated with the OVA solution for 30 min at 37°C, the 
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co-addition of either MK (100 µg/ml) or MP (100 µg/ml) significantly inhibited cysLT 
production (Fig. 8B).  
   Table 2 summarizes the percent ratios of LTC4, LTD4, and LTE4 in cysLTs 
produced from each incubation mixture containing the chopped lung fragments. LTC4 
was a major metabolite and occupied 55-70% of cysLTs produced by incubation for up 










   This study indicates that either cysLT1R antagonist or steroid suppresses LAR and 
infiltration of inflammatory cells into the bronchial submucosa following repeated 
antigen challenge. In a previous study, Henderson et al. (1996) reported that a 
5-lipoxygenase inhibitor inhibited the infiltration of eosinophils into the bronchial wall 
following antigen challenge in a murine asthma model. Equivalent effects have been 
observed using cysLT1R antagonists in similar models (Muñoz et al., 1997). It has 
already been reported that LTE4 shows chemotactic activity toward eosinophils 
(Laitinen et al., 1993). In the present study, a cysLT1R antagonist and a steroid each 
inhibited the accumulation of inflammatory cells in the bronchial submucosa and airway 
space in parallel with a decrease of A-LTE4 excretion into bile. We speculate that the 
decrease in the number of cells accumulated in the lung, especially in the bronchial 
submucosal tissues, contributed to the decreased excretion of A- LTE4 into the bile, 
suggesting a reduction in the generation of cysLTs in the lungs (Powell et al., 1995). In 
support of this idea, we observed a linear relationship between the number of leukocytes 
in BALF and the A-LTE4 levels in bile. Pretreatment with either drug suppressed 
JPET #74922 
 24
bronchoconstriction while maintaining the linear relationship between these two 
parameters. The single pretreatment with MP or MK significantly suppressed A-LTE4 in 
the bile, but did not inhibit number of eosinophils in BALF. These results suggest that 
the cellular origin of cysLTs may come from macrophages rather than from eosinophils 
during LAR, as previously reported (Yu et al., 1995). These results may suggest that the 
suppression in the infiltration of leukocytes into the airway tissues by MP or MK 
contributes to the reduced production of cysLTs in the lungs. However, whether or not 
MK and MP directly reduce cysLT production from the sensitized lungs after antigen 
challenge remained unclear in these in vivo experiments.  
   To further analyze the mechanisms by which the two drugs reduce the generation of 
cysLTs, the effects of either drug on cysLT production in the sensitized chopped lungs 
were evaluated in vitro. The two drugs had different effects on the production of cysLTs 
induced by incubation with the antigen (see Fig.7). While MK reduced cysLT 
production at the high dose, MP showed a diathesis to increase cysLT production from 
the chopped lungs after antigen challenge. This relationship between the two drugs was 
also similar in the experiment using chopped lung fragments after repeated antigen 
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exposure (see Fig.8A). Namely, co-addition of MK at the high dose reduced cysLT 
production from the lungs with or without previous OVA exposure following the 
addition of OVA, but this effect was not observed with MP. This result suggests that 
MK is able to directly suppress the generation of cysLTs in the lung tissue, but MP is 
not. On the other hand, when we performed a similar experiment using the lung 
fragments from rats subjected to repeated OVA exposure and repeated in vivo 
pretreatment with either drug (see Fig. 8B), both drugs suppressed the in vitro 
generation of cysLTs after the third OVA exposure, and the suppression of cysLTs by 
MP was similar to that by MK. Consequently, it is concluded that MP does not directly 
inhibit cysLT generation from the lung tissue following antigen challenge, but MP is 
able to suppress cysLT production in the case of repeated treatment through broad 
anti-inflammatory effects, including inhibition of cellular infiltration into the bronchial 
submucosa after repeated antigen exposure. We could not propose an explanation of 
how cysLT production from the chopped lungs was inhibited by MK. On the other hand, 
Ramires et al. (2003) reported that montelukast directly inhibited 5-lipoxygenase 
activity in mast cells at the lower micromolar ranges when stimulated by calcium 
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ionophore A23187. However, this inhibition required cellular integrity, because MK did 
not inhibit 5-lipoxygenase activity in the homogenates from the cells. The dose of MK 
(100 µg/ml) used in the in vitro study is much higher than the concentrations required to 
block CysLT1R in human lung preparations (Fregonese et al., 2002). However, in our in 
vivo experiments, MK was administered to rats at 10 mg/kg, which is approximately 50 
times more than the usual clinical dosage. Concerning the in vivo dose of MK used in 
the present animal studies, other groups have used similar doses (10-25 mg/kg) (Wu et 
al., 2003; Leick-Maldonado et al., 2004). A blood concentration of 100 µg/ml may be 
hardly achievable after the administration of the in vivo dose at 10 mg/kg. However, 
this concentraion may be achievable if used at high doses of 25 mg/kg or more, because 
the dose at 25 mg/kg raised the blood concentration nearly up to 80 µg/ml as shown by 
Wu et al. (2003). The dose of MK needed to block LTC4 is much higher than that 
needed to block LTD4 (Jones et al., 1995). The ratios of production of LTC4 to LTD4 in 
the rat lungs in the present study suggests that conversion of LTC4 to LTD4 was slower 
in this species than in human beings (see Table 2). Concerning human chopped lung, 
Kumlin and Dahlen (1990) reported that LTC4 was rapidly converted to LTD4 and LTE4, 
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and only 10% of LTC4 remained intact after 30 min of incubation at 37°C. 
Consequently, the discrepancy in γ-glutamyl transpeptidase activity between the two 
species may be one reason that the dose of cysLT1RA required to ameliorate asthma in 
rats is higher than that in humans (Shi et al., 2001).  
   With respect to the two administration schedules used in this study, both were 
effective at inhibiting late bronchoconstriction, cellular infiltration into the bronchial 
submucosa, and cysLT production in the lungs, but the triple pretreatment regimen 
resulted in more complete suppression than the single pretreatment regimen.  These 
results suggest that both drugs are also effective for treatment in the later advanced 
stages of the disease, when inflammation is already present. MP seemed to show similar 
but more potent effects than MK did. These results may be compatible with the previous 
clinical observation that severe asthma attack was not always ameliorated by cysLT1R 
antagonists alone, but required co-administration of steroids (Tomari et al., 2001). This 
result provides further evidence for the effectiveness of steroids and cysLT1RAs on 
allergic disorders as anti-inflammatory therapy. Concerning anti-inflammatory effects, 
Wu et al. (2003) reported that high doses of MK exerted anti-inflammatory effects in an 
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animal model of acute asthma by inhibiting cytokine production. Since steroids have 
various anti-inflammatory and immunosuppressive effects on allergic reactions, 
including inhibition of cytokine gene induction, inhibition of chemokine synthesis, 
repression of genes encoding cell surface receptors, and repression of adhesion 
molecules involved in leukocyte activation, migration, and recruitment (Karin, 1998), 
the present finding that the effects of the cysLT1R antagonist were almost equal to those 
of the steroid suggests that cysLTs play a major role in allergic asthma through 
cysLT1R, as supported by previous reports using receptor-disrupted mice (Maekawa et 
al., 2002). 
   In conclusion, this study revealed that MK may have the novel effect of directly 
inhibiting cysLT generation when administered at a high dose, in addition to the 
previously reported ameliorative effects of cysLT1R antagonists on bronchoconstriction, 
recruitment of inflammatory cells into loci, and inflammation (Wu et al., 2003). The 
finding that MK and MP had different effects on cysLT production may provide a 
further rationale for the use of combination therapy with cysLT1RAs and steroids for 
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LEGENDS FOR FIGURES 
 
Fig.1. Experimental schedules for the exposure of sensitized rats to OVA and 
pretreatment with MK, MP, or saline. Certain rats were exposed to the antigen by 
inhalation of OVA aerosol, and the final challenge was conducted by an i.t. 
administration of OVA solution. A) Triple OVA exposure with triple pretreatment 
before every exposure; B) triple OVA exposure with a single pretreatment only before 
the 3rd exposure; and C) single OVA exposure with pretreatment. 
 
Fig. 2. A. Time course of changes in pulmonary resistance (RL) after the 3rd OVA 
exposure to actively sensitized rats with or without pretreatment with MK (10 mg/kg, 
gastrically) or MP (10 mg/kg, intramuscularly) 1 hour before every OVA exposure. 
Control rats were given 0.1 ml saline i.t. instead of OVA solution namely, triple 
administration of saline. B. Time course of RL changes after the 3rd OVA exposure in 
rats pretreated with MK (10 mg/kg) or MP (10 mg/kg) only before the final OVA 
exposure. The rats inhaled OVA aerosol for the last 2 consecutive days. The baseline 
value of saline was 0.217+0.003 cm H2O/(ml/s). The baseline value of each group 
differed from that of the saline group by less than 10%. Data are expressed as a 
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percentage of the baseline value (RL value before challenge = 100%) and presented as 
the means+SEM. *p<0.05, **p<0.01 between the positive control group (OVA day 3 + 
saline) and the OVA day 3 + MK group;  +p<0.05, ++p<0.01 between the positive 
control group and OVA day 3 + MP group.  
 
Fig. 3. Cytological studies for changes in leukocyte number and cellular differentiation 
in broncho-alveolar lavage fluid (BALF) and effects of MK and MP. A. Pretreatment 
with MK (10 mg/kg) or MP (10 mg/kg) was performed 1 hour before every OVA 
exposure. The number of total inflammatory cells in BALF was counted 6 hours after 
the 2nd or 3rd OVA challenge. Cellular differentiation of the infiltrating inflammatory 
cells showed that the levels of neutrophils (No), eosinophils (Eo), lymphocytes (Ly), 
and macrophages (Mo) were recovered in BALF 6 hours after the 2nd or 3rd OVA 
challenge. Control rats were given 0.1 ml saline i.t. instead of OVA solution. B. 
Pretreatment with MK (10 mg/kg) or MP (10 mg/kg) was performed only before the 3rd 
exposure. Values are presented as the means+SEM. *p<0.05, **p<0.01 between the 
positive control group (OVA day 3 + saline) and the OVA day 3 + MK group;  +p<0.05, 
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++p<0.01 between the positive control group and OVA day 3 + MP group. 
 
Fig. 4. Histological findings in bronchial tissues after the 3rd OVA exposure of actively 
sensitized rats and the effects of pretreatment with MK or MP. A, double OVA exposure 
(OVA Day 2 + saline); B, triple OVA exposure (OVA Day 3 + saline); C, triple OVA 
exposure with triple pretreatment with MK (10 mg/kg) before every exposure; D, triple 
OVA exposure with triple pretreatment with MP (10 mg/kg) before every exposure; E, 
triple OVA exposure with single pretreatment with MK (10 mg/kg) only before the 3rd 
exposure; F, triple OVA exposure with single pretreatment with MP (10 mg/kg) only 
before the 3rd exposure. The upper and lower panels show x40 and x400 magnification 
by light microscopy following H.E. staining, respectively. 
 
Fig. 5. Estimation of N-acetyl-leukotriene E4 excreted in the biliary fluid after the 3rd 
OVA exposure and effects of pretreatment with MK (10 mg/kg) and MP (10 mg/kg). 
A-LTE4 was measured as described in the MATERIALS and METHODS and expressed 
as ng/ml bile per hour for consecutive periods commencing 1 hour before challenge up 
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to 6 hours after OVA challenge. A. Pretreatment with MK (10 mg/kg) or MP (10 mg/kg) 
was performed 1 hour before every OVA exposure. B. MK (10 mg/kg) or MP (10 
mg/kg) was pretreated only before the 3rd exposure. Values are presented as the 
means+SEM. *p<0.05 between the positive control group (OVA Day 3 + saline) and 
OVA day 3 + MK group; +p<0.05, ++p< 0.01 between the positive control group and 
OVA day 3 + MP group.  
 
Fig. 6. Relationship between the amount of N-acetyl-LTE4 in bile and total number of 
leukocytes in BALF at 6 hour after the 3rd OVA exposure with or without pretreatment 
of MK or MP. A. Pretreatment with MK (10 mg/kg) or MP (10 mg/kg) was performed 1 
hour before every OVA exposure. B. Pretreatment with MK (10 mg/kg) or MP (10 
mg/kg) was performed only before the 3rd exposure. 
 
Fig. 7. Generation of cysLTs from the lung fragments without previous OVA exposure 
by stimulation with OVA and effects of co-addition with MK or MP. Various doses of 
MK or MP (1–100 µg/ml) were added to the incubation mixture, which contained 300 
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mg chopped sensitized lung fragments. Each mixture containing either drug was 
preincubated for 5 min at 37°C, and then further incubated for 30 min after the addition 
of OVA (final concentration = 100 µg/ml).Values are presented as the means+SEM 
(n=3-10). *p<0.05 and **p<0.01 compared to the controls.  
 
Fig. 8. Generation of cysLTs from the lung fragments with previous OVA exposure by 
stimulation with the 3rd OVA challenge and effects of co-addition with MK or MP. (A) 
Sensitized rats were exposed to the antigen by inhalation of OVA aerosol for the last 2 
consecutive days without pretreatment, and the next day the lungs were removed and 
cut in small pieces (chopped lung). Each incubation mixture containing 300 mg 
chopped lung fragments was preincubated for 5 min at 37°C in the presence or absence 
of MK (100 µg/ml) or MP (100 µg/ml), and then in vitro challenged with OVA (final 
concentration = 100 µg/ml) and incubated for 30 min at 37°C. Saline was used in place 
of OVA solution for the controls. (B) Sensitized rats were exposed to the antigen by 
inhalation of OVA aerosol for the last 2 consecutive days with or without pretreatment 
of MK (10 mg/kg) or MP (10 mg/kg) before every exposure. The next day, the lungs 
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were removed and cut in small pieces (chopped lung). Each incubation mixture 
containing 300 mg chopped lung fragments in the presence or absence of MK (100 
µg/ml) or MP (100 µg/ml) was similarly incubated as in (A). Values are presented as the 
means+SEM (n=4-8). *p<0.05 and **p<0.01 compared to the controls. 
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